Table 2.
Clinical characteristics and neuropathological diagnoses of deceased participants with completed autopsy
| Total | Biomarker negative | Biomarker positive | P-valuea | ||||
|---|---|---|---|---|---|---|---|
| n | Mean (SD) or % | n | Mean (SD) or % | n | Mean (SD) or % | ||
| Age at baseline, mean (SD), years | 57 | 78.8 (6.9) | 35 | 79.0 (7.3) | 22 | 78.6 (6.3) | 0.8310 |
| Age at death, mean (SD), years | 57 | 85.5 (7.5) | 34 | 85.9 (8.3) | 19 | 86.3 (6.9) | 0.8546 |
| Male sex, % | 25 | 43.9 | 17 | 48.6 | 8 | 36.4 | 0.3681 |
| Race, % | |||||||
| Non-Hispanic White | 53 | 93.0 | 32 | 91.4 | 21 | 95.4 | 0.5619 |
| African-American | 4 | 7.0 | 3 | 8.6 | 1 | 4.6 | 0.5619 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | – |
| More than one | 0 | 0 | 0 | 0 | 0 | 0 | – |
| APOE ɛ4 carriers, % | 14 | 24.6 | 4 | 11.4 | 10 | 45.4 | 0.0036 |
| Education, mean (SD), years | 57 | 16.2 (3.1) | 35 | 15.8 (2.7) | 22 | 16.7 (3.6) | 0.3158 |
| Interval from baseline assessment to death, mean (SD) [median], years | 57 | 7.2 (3.3) [7.2] | 35 | 6.9 (3.3) [7.2] | 22 | 7.6 (3.3) [7.2] | 0.4434 |
| Interval from baseline biomarker to death, mean (SD) [median], years | 57 | 7.0 (3.2) [7.0] | 35 | 6.8 (3.2) [7.3] | 22 | 7.4 (3.2) [6.9] | 0.4657 |
| Progression to CDR > 0 at expiration, % | 32 | 56.1 | 17 | 48.6 | 15 | 68.2 | 0.1471 |
| CDR at expiration, % | |||||||
| 0 | 25 | 43.9 | 18 | 51.4 | 7 | 31.8 | 0.1471 |
| 0.5 | 11 | 19.3 | 9 | 25.7 | 2 | 9.1 | 0.1211 |
| 1 | 4 | 7.0 | 3 | 8.6 | 1 | 4.6 | 0.5619 |
| 2 | 5 | 8.8 | 2 | 5.7 | 3 | 13.6 | 0.3030 |
| 3 | 12 | 21.0 | 3 | 8.6 | 9 | 40.9 | 0.0035 |
| Intermediate-high ADNC b , % | 23 | 40.3 | 3 | 8.6 | 20 | 90.9 | <0.0001 |
| ADNC by severity, % | |||||||
| None | 7 | 12.3 | 7 | 20.0 | 0 | 0 | 0.0251 |
| Low | 27 | 47.4 | 25 | 71.4 | 2 | 9.1 | <0.0001 |
| Intermediate | 9 | 15.8 | 1 | 2.9 | 8 | 36.4 | 0.0007 |
| High | 14 | 24.5 | 2 | 5.7 | 12 | 54.5 | <0.0001 |
| No. defined by CSF biomarker, % | 20 | 35.1 | 12 | 60.0 | 8 | 40.0 | 0.2077 |
| Intermediate-high ADNC, % CSF group | 9 | 45.0 | 1 | 8.3 | 8 | 100.0 | <0.0001 |
| Elecsys t-tau, mean (SD), pg/ml | 20 | 253.556 (135.095) | 12 | 188.152 (66.145) | 8 | 351.662 (155.978) | 0.0213 |
| Elecsys p-tau181, mean (SD), pg/ml | 20 | 24.238 (15.961) | 12 | 15.579 (5.263) | 8 | 37.227 (18.071) | 0.0113 |
| Elecsys Aβ42, mean (SD), pg/ml | 20 | 1277.65 (619.144) | 12 | 1622.28 (552.519) | 8 | 760.700 (227.481) | 0.0002 |
| p-tau181/Aβ42 Ratio, mean (SD) | 20 | 0.0264 (0.0262) | 12 | 0.0099 (0.0024) | 8 | 0.0512 (0.0262) | 0.0029 |
| No. defined by amyloid PET biomarker, % | 37 | 64.9 | 23 | 62.2 | 14 | 37.8 | 0.0366 |
| Intermediate-high ADNC, % PET group | 14 | 37.8 | 2 | 8.7 | 12 | 85.7 | <0.0001 |
| PIB SUVR, mean (SD) | 32 | 1.605 (0.935) | 20 | 1.025 (0.122) | 12 | 2.572 (0.899) | <0.0001 |
| AV45 SUVR, mean (SD) | 5 | 1.393 (0.589) | 3 | 1.109 (0.196) | 2 | 1.818 (0.840) | 0.2258 |
a
P-values derived from tests comparing mean or % values between biomarker-negative and -positive subgroups. P-values < 0.05 are highlighted in bold.
b
Defined by NIA-Regan intermediate-to-high likelihood of Alzheimer's diseaseee or NIA-AA intermediate-to-high ADNC. Row highlighted in bold indicates main finding from this table.